NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Behavioral Change Following Alzheimer's Disease (AD) Biomarker Disclosure

CompletedNA

Sponsor: University of Michigan

Conditions: Mild Cognitive Impairment, Alzheimer Disease, Amnestic Mild Cognitive Disorder

Interventions: Diagnostic Disclosure Protocol, Biomarker Disclosure Protocol

Countries: United States

The proposed project will assess long-term changes to health/lifestyle, advanced planning, and research engagement that Black and White patients with Amnestic Mild Cognitive Impairment (aMCI) make following disclosure of positron emission tomography-based amyloid and tau burden and associated risk of conversion to Dementia-Alzheimer's Type. Healthcare access will be explored as potential barrier to or facilitator of behavior change.

Eligibility overview

Sex: ALL

Age: 50 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Diagnosed with Amnestic Mild Cognitive Impairment within the past 12 months,
* Available PET Aβ and tau imaging

Exclusion Criteria:

* Significant neurologic diagnosis (e.g., Alzheimer's dementia or other neurodegenerative dementia, Parkinson's disease, seizure disorder, tumor, multiple sclerosis)
* Neurologic injury (e.g., significant stroke or moderate-severe head injury, defined by loss of consciousness \> 5 minutes, presence of significant post-traumatic amnesia, or the need for extended hospitalization or intervention)
* Motor abnormalities indicative of a non-AD etiology
* Severe mental illness (e.g., bipolar disorder, psychosis), moderate-severe mood or anxiety disorder, active substance use disorder (o reduce the likelihood of severe psychological distress, participants must screen negative for moderate-severe depressive or anxiety symptoms at study enrollment.)
* Inability to provide independent informed consent.

Locations (1)

Ann Arbor, Michigan, United States